Subscribe
shutterstock_787266955_willy_barton
will barton / Shutterstock.com
25 July 2019Big PharmaSarah Morgan

Vaccines growth offsets Advair generic pain for GSK

Growth in GlaxoSmithKline’s (GSK) vaccines and consumer healthcare divisions has managed to partly counter the impact of generic versions of Advair (fluticasone propionate/salmeterol) on its sales.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
GSK seeks to boost oncology repertoire with $5.1bn acquisition
3 December 2018   GSK has agreed to buy US oncology company Tesaro for $5.1 billion, in a move designed to strengthen its anti-cancer offering.
Americas
GSK sues Chinese company over Advair Diskus TMs
26 March 2019   Pharmaceutical company GSK has taken a Chinese company to court over its alleged “deliberate and unlawful campaign” to copy GSK’s trademarks.
Big Pharma
Ionis licenses chronic hepatitis B treatments to GSK
28 August 2019   Biotech company Ionis Pharmaceuticals is to license its antisense medicines, used to treat people with chronic hepatitis B, to GlaxoSmithKline.


Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024

Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

More on this story

Americas
GSK seeks to boost oncology repertoire with $5.1bn acquisition
3 December 2018   GSK has agreed to buy US oncology company Tesaro for $5.1 billion, in a move designed to strengthen its anti-cancer offering.
Americas
GSK sues Chinese company over Advair Diskus TMs
26 March 2019   Pharmaceutical company GSK has taken a Chinese company to court over its alleged “deliberate and unlawful campaign” to copy GSK’s trademarks.
Big Pharma
Ionis licenses chronic hepatitis B treatments to GSK
28 August 2019   Biotech company Ionis Pharmaceuticals is to license its antisense medicines, used to treat people with chronic hepatitis B, to GlaxoSmithKline.

More on this story

Americas
GSK seeks to boost oncology repertoire with $5.1bn acquisition
3 December 2018   GSK has agreed to buy US oncology company Tesaro for $5.1 billion, in a move designed to strengthen its anti-cancer offering.
Americas
GSK sues Chinese company over Advair Diskus TMs
26 March 2019   Pharmaceutical company GSK has taken a Chinese company to court over its alleged “deliberate and unlawful campaign” to copy GSK’s trademarks.
Big Pharma
Ionis licenses chronic hepatitis B treatments to GSK
28 August 2019   Biotech company Ionis Pharmaceuticals is to license its antisense medicines, used to treat people with chronic hepatitis B, to GlaxoSmithKline.

More features

Bayer gains exclusive licence for heart drug in Japan
EPO delivers key Novo Nordisk, GSK and Inhibrx rulings
McGuireWoods expands team with ex-Novo Nordisk GC
Paul, Weiss swoops for senior duo from Weil, Gotshal
UPC bans Meril Life Sciences from selling infringing heart valve
SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic
Kathi Vidal to rejoin previous firm as partner following USPTO departure
GSK triumphs in EPO appeal, revoking Pfizer patent